MAH: marketing authorisation holder
The marketing authorisation holder (MAH) is the company named in the authorisation and legally responsible for the medicine on the EU market.
Also known as: marketing authorization holder, MA holder, licence holder
3 min readUpdated
Reviewed by Gosia Luksza, CEO at Regunaut
At a glance
- Legal basis
- Articles 6(1a) and 8(2), Directive 2001/83/EC; Article 2, Regulation (EC) No 726/2004
- Must be
- Established in the EU or EEA
- Responsible for
- The dossier, safety monitoring, product information and supply
- Not the same as
- The manufacturer, the distributor or the local representative
How it works
The holder is the natural or legal person to whom the authorisation is granted and whose name appears in the decision, in the product information and on the pack. Article 8(2) of Directive 2001/83/EC allows an authorisation to be granted only to an applicant established in the Union, which in practice means the European Economic Area, and Article 2 of Regulation (EC) No 726/2004 says the same for centrally authorised products. Article 6(1a) of the Directive makes the holder responsible for marketing the product and adds that designating a representative does not relieve the holder of its legal responsibility.
The obligations follow from that responsibility. The holder keeps the dossier and the product information up to date with scientific knowledge and files the variations this requires (Article 23). It tells the authority when the product is actually placed on the market and, at least two months in advance, when marketing will stop (Article 23a). It operates a pharmacovigilance system with a qualified person and a master file, submits safety reports and maintains the risk management plan (Article 104). It runs a scientific service in charge of information about its products (Article 98) and, with its distributors, ensures appropriate and continued supply (Article 81). It pays the fees, answers the authority's requests and is the addressee of any suspension, revocation or referral decision.
The holder is often not the company that makes or sells the product. The manufacturer holds a manufacturing and importation authorisation and certifies each batch through its qualified person; the holder may contract all manufacturing out, but it remains responsible for the product matching its authorisation. The local representative, defined in Article 1(18a) of the Directive, represents the holder in a Member State and is named in the package leaflet without taking over the holder's legal responsibility. Distributors need their own wholesale distribution authorisation. A group may hold its authorisations in one entity or in several national affiliates, and moving them between entities requires an MAH transfer.
What goes wrong
A holder entity that exists on paper but cannot show that it controls pharmacovigilance, quality complaints and recalls, which inspectors test; contracts with manufacturers, distributors and licensing partners that leave gaps in who reports adverse reactions or who files variations; a holder that ends up established outside the EEA after a corporate change or, as happened when the United Kingdom left the EU, a change in the country's status; different holder entities for the same product in different Member States with nobody keeping the dossiers aligned; and changes to the holder's name or address that are not notified immediately as a Type IAIN variation.
What teams do with it in Regunaut
Jobs in the platform that turn on MAH, each part of a wider workflow.
- WorkbenchBuild an MAH transfer checklistA step-by-step view of what needs to be done, and when, to move a marketing authorisation to a new holder.Part of Regulatory lifecycle planning
- Workbench quick task · LifecyclePrepare regulatory due diligenceSummarise authorisations, open commitments, and unresolved risks.Part of Pharma competitive intelligence
What the 2026 EU pharma package changes
Under the new pharma package (not yet in force), holders take on further duties, including a shortage prevention plan for prescription medicines and at least twelve months' notice before permanently ceasing supply; see shortage changes.
MAH: common questions
What is a marketing authorisation holder?
The marketing authorisation holder is the person or company to which a medicine's authorisation has been granted. It is named in the authorisation and on the pack, and it is legally responsible for the product: keeping the dossier current, monitoring safety, maintaining the product information and making sure the product is supplied.
Does the MAH have to be based in the EU?
Yes. Article 8(2) of Directive 2001/83/EC allows a marketing authorisation to be granted only to an applicant established in the Union, and Article 2 of Regulation (EC) No 726/2004 requires the same of holders of centralised authorisations. In practice establishment anywhere in the European Economic Area is accepted. A company outside the EEA needs an EEA entity to hold the authorisation.
What is the difference between the MAH and the manufacturer?
The holder owns the authorisation and carries the regulatory responsibility for the product. The manufacturer holds a manufacturing authorisation, makes or imports the product and certifies each batch through its qualified person. They can be the same company, but often are not, and the holder remains responsible when manufacturing is contracted out.